Co-Authors
This is a "connection" page, showing publications co-authored by FASIHA KANWAL and SAIRA KHADERI.
Connection Strength
2.790
-
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet. Hepatology. 2022 09; 76(3):546-548.
Score: 0.871
-
Project ECHO: The Specialist Will See You Now. Hepatology. 2018 12; 68(6):2066-2068.
Score: 0.686
-
Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
Score: 0.240
-
Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
Score: 0.234
-
Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
Score: 0.231
-
Cirrhosis Quality Collaborative. Clin Gastroenterol Hepatol. 2022 05; 20(5):970-972.
Score: 0.215
-
Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut. 2024 Feb 16.
Score: 0.062
-
Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
Score: 0.058
-
Early Impact of MMaT-3 Policy on Liver Transplant Waitlist Outcomes for Hepatocellular Carcinoma. Transplant Direct. 2022 May; 8(5):e1313.
Score: 0.054
-
Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol. 2020 Sep 27; 12(9):628-640.
Score: 0.049
-
Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
Score: 0.047
-
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
Score: 0.044